When is a PMCF plan required under EU MDR, and what has to go in a PSUR?
Clinical evidence under Regulation (EU) 2017/745 does not stop at CE marking. The clinical evaluation report fixes what is known at conformity assessment; post-market surveillance keeps that position current while the device is on the market. Article 83 builds the system, Article 84 plans it, Annex XIV Part B generates the clinical data, Articles 85 and 86 report it. Reviewers read these as one loop.
The PMS system under Article 83 and the PMS plan under Article 84
Article 83 requires a manufacturer to establish a post-market surveillance system, proportionate to risk class and device type, that continuously checks development-phase results against real-world data on safety and performance. The obligation is system-level: it is not discharged by one report at the end of a period, and the system must be documented as running.
Article 84 requires that system to be based on a PMS plan defining what data is needed, how it is collected and how it is assessed, across several downstream functions: updating the risk management file and design and manufacturing information, feeding the clinical evaluation, and detecting trends. The PMS plan is the parent document; the PMCF plan sits inside it as the clinical data-generation component.
What Annex XIV Part B requires a PMCF plan to do
Annex XIV Part B places PMCF inside the PMS system and specifies what the plan's methods must achieve:
- confirm safety and performance throughout the expected lifetime of the device;
- identify previously unknown side-effects;
- monitor the rate and severity of known side-effects;
- identify and analyse emergent risks;
- ensure the continued acceptability of the benefit-risk determination;
- identify possible systematic misuse or off-label use.
The Annex separates two method families. General procedures cover collection of clinical experience, user feedback, and screening of scientific literature. Specific methods cover activities such as registry evaluation and dedicated PMCF studies. Both require a detailed justification of adequacy and a time schedule.
The load-bearing word is justification. A plan listing a literature screen and a complaint review, without explaining why those mechanisms catch emergent risks and off-label use for this device and population, has stated activities rather than justified a method.
If you intend not to run PMCF activities
Where a manufacturer takes the position that PMCF activities are not needed, that position has to be reasoned in the documentation rather than asserted. The exact wording of the justification requirement should be confirmed against the current Annex XIV Part B text; the framing here follows the structure of that Annex and is otherwise unverified. A defensible justification walks through the same six aims and shows, for each, why existing pre-market evidence, complaint handling, vigilance trending and literature screening already satisfy it.
PMCF plan and PMCF evaluation report: the MDCG templates
MDCG 2020-7 provides a PMCF plan template covering safety confirmation, side-effect identification, emerging risk analysis, benefit-risk verification and misuse detection, with justification requirements for study design and timelines. MDCG 2020-8 provides the PMCF evaluation report template: manufacturer details, device description, results of the activities performed, evaluation of the clinical data obtained, and conclusions including preventive or corrective measures.
The plan is forward-looking; the evaluation report is backward-looking. What matters is what happens after the evaluation report is signed: its conclusions return to the clinical evaluation report. PMCF exists to update the clinical evaluation with real-world confirmation, or contradiction, of what was claimed at CE marking. A report that has not absorbed the latest PMCF findings has detached from post-market experience, and the document dates show it.
PSUR periodicity under Article 86
Article 86 sets the Periodic Safety Update Report and its update frequency by risk class:
- Class IIa: the PSUR must be updated at least every two years, and when necessary (Article 86, MDR 2017/745).
- Class IIb: the PSUR must be updated at least annually (Article 86, MDR 2017/745).
- Class III: the PSUR must be updated at least annually and submitted via EUDAMED to the notified body (Article 86, MDR 2017/745).
Two scope limits. Whether "at least every two years" for Class IIa runs on calendar or rolling years is not settled by the wording relied on here, so treat any reading as unverified. And the itemised PSUR content list is not restated here, because only the periodicity above is confirmed by the sources behind this page; draft content from the Article text itself.
The PMS report under Article 85 for lower-class devices
Article 85 covers the equivalent reporting obligation for Class I and Class II devices, under which manufacturers prepare a Post-Market Surveillance Report. Its update interval is not confirmed by the sources behind this page and is left unstated rather than guessed; verify it against the current Article 85 text before fixing a reporting cycle.
Class III and implantable devices: the SSCP under Article 32
For implantable and Class III devices, Article 32 adds a Summary of Safety and Clinical Performance written for end users: healthcare professionals and, where applicable, patients. It must give a balanced summary of both favourable and unfavourable safety and clinical effectiveness data, including residual risks and mitigation, and it goes to a notified body for validation before publication in EUDAMED. MDCG 2019-9 Rev.1 sets a mandatory eight-section structure, from device identification and intended use through to user training and standards. Because it is published, language overstating performance is exposed there first.
How the documents chain together
- Clinical evaluation report establishes the baseline clinical evidence and benefit-risk conclusion at CE marking (Article 61, Annex XIV Part A).
- PMCF plan defines how that conclusion is confirmed or challenged with real-world data (Annex XIV Part B; MDCG 2020-7).
- PMCF evaluation report documents what the activities found and what measures they trigger (MDCG 2020-8).
- PSUR (Article 86) or PMS report (Article 85) consolidates PMCF findings with complaint, vigilance and trend data.
- Updated clinical evaluation report absorbs those conclusions and becomes the next baseline; for implantable and Class III devices the SSCP is refreshed in step.
A break anywhere in that chain is what a reviewer looks for: a PMCF evaluation report whose findings never appear in the clinical evaluation report, or a PSUR repeating the previous period's conclusions without engaging new PMCF data.
Device class, document and frequency at a glance
| Device class | Post-market document | Update frequency |
|---|---|---|
| Class I and Class II (general) | Post-Market Surveillance Report (Article 85) | Not confirmed here; verify against current Article 85 text |
| Class IIa | PSUR (Article 86) | At least every two years, and when necessary |
| Class IIb | PSUR (Article 86) | At least annually |
| Class III | PSUR (Article 86), submitted via EUDAMED to the notified body | At least annually |
| Implantable and Class III | SSCP (Article 32), published in EUDAMED | Kept in step with the clinical evaluation |
Which MDCG guidance applies to which step
| Guidance | Subject | Where it bites |
|---|---|---|
| MDCG 2020-1 | Clinical evaluation of medical device software | Valid clinical association; technical, analytical and clinical performance |
| MDCG 2020-5 | Equivalence | Three-pillar demonstration; cumulative effect and gap analysis |
| MDCG 2020-6 | Legacy devices under 93/42/EEC or 90/385/EEC | Sufficient clinical evidence; evidence hierarchy |
| MDCG 2020-7 | PMCF plan template | Method justification and time schedule |
| MDCG 2020-8 | PMCF evaluation report template | Results and preventive or corrective measures |
| MDCG 2020-13 | Clinical Evaluation Assessment Report | How a notified body records assessment conclusions |
| MDCG 2019-9 Rev.1 | SSCP | Eight-section structure; audience-specific presentation |
MDCG 2020-13 is a July 2020 publication; whether it remains the current template is unverified here, and MDCG 2023-7 on Article 61 should be checked alongside it.
Recurring deficiencies that surface at the PMCF stage
Deficiencies on clinical evaluation and PMCF documentation cluster into recurring patterns:
- PMCF not justified. Weak rationale for study design or sample sizes; residual risks and data gaps unaddressed; PMCF treated as a post-approval task rather than evidence generation.
- State of the art not established. Literature search neither prespecified nor reproducible; PRISMA flow diagrams and audit trails missing; appraisal criteria vague or inconsistently applied.
- Equivalence not substantiated. Demonstration missing across one or more of the technical, biological and clinical pillars, or insufficient access to reference device data (Annex XIV Part A Section 3).
- Clinical data insufficient for the intended purpose. Evidence not aligned to the stated patient populations, device variants and user groups, and not stratified by them.
- Benefit-risk not quantified. Objectives without measurable outcomes; conclusions unsupported by quantitative comparison against the state of the art.
- Technical file without a narrative. No logical progression from conception through testing; weak links between risks, hazards and verification evidence.
Most originate upstream. An unjustified PMCF position on top of an unquantified benefit-risk conclusion compounds the problem: the reviewer has neither a baseline nor a mechanism for closing it.
Where Clinoble fits
Clinoble Innovations Private Limited is based in Hyderabad, Telangana, India. Founder and director: Dr. Jaideep Rao M., MBBS, MD Community Medicine. Two Indian patent applications are pending in quantitative clinical imaging, IND 202641088451 and IND 202641090786.
Clinoble works on the clinical evidence half of this chain: structuring a clinical evaluation plan against Annex XIV Part A, running a prespecified and reproducible literature search to establish state of the art, and setting out how PMCF findings route back into the clinical evaluation report. Details are on the clinical evaluation services page. Its own products, including CardioPulmo and TB F.I.R.S.T, are built as screening aids and triage support for clinicians, not as instruments that determine a diagnosis.
This page is background reading, not legal or regulatory advice. Confirm every requirement above against the current text of Regulation (EU) 2017/745 and the MDCG guidance applicable to your device class.
Working through a PMCF justification, or routing PMCF findings back into a clinical evaluation report?